The Clorox Company

Based on a comprehensive analysis of Clorox (CLX), the stock presents a compelling but nuanced case. Fundamentally, the company has demonstrated impressive operational improvements, with revenue growth accelerating to 17% quarter-over-quarter and net income nearly doubling. This indicates strong execution and effective cost management are taking hold after a challenging period.

Technically, CLX is exhibiting robust bullish momentum, significantly outperforming the market with a 20% gain over the past three months. This recovery is notable for its lower volatility, as indicated by the stock's low beta. However, investors must weigh this against a strained liquidity position and a potentially negative shareholder equity structure, which pose fundamental risks.

Buy Recommendation:

CLX offers a compelling turnaround story backed by strong recent operational execution and positive price momentum. The current valuation appears reasonable relative to earnings, and the low beta provides a defensive characteristic. While the weak balance sheet is a concern, the company's powerful brand portfolio and significant earnings rebound suggest the recovery is substantive. For investors seeking a staples name with recent positive momentum, CLX represents a worthwhile consideration at this stage.

RockFlow Model Forecast: Three Scenarios for 2026

Based on the provided analysis, here is a 12-month outlook for Clorox (CLX):

12-Month Outlook for CLX

The outlook for CLX over the next year is cautiously optimistic, hinging on the company's ability to sustain its operational turnaround. The key catalysts will be the continuation of strong revenue growth and disciplined cost management, which could drive further earnings surprises and validate the recovery narrative. However, the primary risk remains the company's strained balance sheet and negative shareholder equity, which could limit financial flexibility and amplify the impact of any operational missteps or economic downturns. Given the lack of a specific analyst target, a reasonable price target range would be in the $130-$150 zone, contingent on the successful execution of the turnaround plan and stabilization of the balance sheet.

Wall Street Consensus

Most Wall Street analysts are optimistic about The Clorox Company's 12-month outlook, with consensus target around $125.94, indicating expected upside potential.

Overall, CLX has investment potential but also faces challenges. Here are key factors to weigh before investing.

CLX has demonstrated robust momentum recently, significantly outpacing the market over the past quarter. The stock has delivered strong double-digit gains, reflecting a potent recovery from its 52-week low.

CLX has posted impressive short-term gains of 13.04% over one month and 20.3% over three months, substantially outperforming the market as indicated by its 20.25% relative strength. This performance highlights a period of significant bullish momentum, especially notable given its low beta, which suggests these gains were achieved with lower volatility than the broader market.

Currently trading at $125.94, CLX sits approximately 30% above its 52-week low but remains about 21% below its 52-week high, placing it in the middle of its yearly range. While the recent surge is impressive, the notable maximum drawdown of -38.04% over the past year serves as a reminder of its recent volatility, suggesting the stock is neither extremely overbought nor oversold at this juncture.

Revenue & Profitability CLX demonstrated strong quarterly revenue growth of roughly 17% from Q1 to Q2, increasing from $1.43 billion to $1.67 billion. Profitability improved significantly, with net income nearly doubling to $157 million, driving the net profit margin up to 9.4% from 5.6% in the prior quarter. This suggests effective cost management and improved operational leverage during the period.

Financial Health The company exhibits concerning liquidity with a current ratio of 0.74 and a very low cash ratio of 0.10, indicating potential short-term obligations strain. The debt ratio of 57% is manageable, but the negative debt-to-equity ratio and long-term debt-to-capitalization exceeding 100% signal a potentially negative shareholder equity position that warrants careful monitoring.

Operational Efficiency Operational metrics show mixed results, with a respectable operating cash flow to sales ratio of 18.6% and a solid interest coverage ratio of 8.6x. However, operational efficiency is hampered by a negative return on equity and a modest asset turnover of 0.30, suggesting potential challenges in generating returns from its asset base and shareholder capital.

Valuation Level: CLX's TTM and forward P/E ratios around 19.5 suggest reasonable valuation relative to historical consumer staples norms, though this needs industry context for full assessment. The extremely high PB ratio of 435 reflects significant intangible brand value characteristic of consumer goods companies, while the low PEG ratio of 0.20 indicates strong growth expectations are embedded in the current price. The elevated EV/EBITDA of 51.2 suggests the market is pricing in premium cash flow expectations.

Peer Comparison: Without specific industry average data, a precise peer benchmarking cannot be conducted. However, CLX's valuation metrics would typically be compared against major household and personal care peers like Procter & Gamble, Colgate-Palmolive, and Church & Dwight to determine relative attractiveness. The absence of industry benchmarks limits the ability to conclude whether CLX trades at a premium or discount to its sector.

Volatility Risk CLX demonstrates significantly lower volatility than the broader market, evidenced by its Beta of 0.607, implying it is about 39% less volatile. However, the stock's substantial 1-year maximum drawdown of -38.04% indicates it has experienced severe price declines, suggesting that while its day-to-day movements are muted, it is not immune to significant downturns during market stress.

Other Risks The absence of notable short interest suggests the market consensus on CLX is not overtly bearish, reducing the risk of a short squeeze or aggressive selling pressure from that quarter. Investors should, however, monitor other fundamental risks such as consumer spending trends and input cost inflation, which are critical for a consumer staples company like Clorox.